STAGE IV URETHRAL CANCER AJCC V8
Clinical trials for STAGE IV URETHRAL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV URETHRAL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV URETHRAL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo shows promise for Tough-to-Treat bladder cancer
Disease control OngoingThis study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced urothelial cancer (a type of bladder cancer) that has spread or come back. The study includes 72 adults who cannot take t…
Matched conditions: STAGE IV URETHRAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:42 UTC
-
Could a common heart drug boost cancer immunotherapy?
Disease control OngoingThis study tests adding propranolol, a blood pressure drug, to standard immunotherapy for people with advanced bladder cancer that has spread. The goal is to see if the combination is safe and may help control the disease. Only 6 participants were enrolled, so results are very ea…
Matched conditions: STAGE IV URETHRAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 01, 2026 15:39 UTC
-
Immunotherapy plus chemo shows promise for Tough-to-Treat cancers
Disease control OngoingThis early-stage trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. About 15 adults whose cancer has spread will receive the combination. T…
Matched conditions: STAGE IV URETHRAL CANCER AJCC V8
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC